Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation.

Ciardiello C, Leone A, Lanuti P, Roca MS, Moccia T, Minciacchi VR, Minopoli M, Gigantino V, De Cecio R, Rippa M, Petti L, Capone F, Vitagliano C, Milone MR, Pucci B, Lombardi R, Iannelli F, Di Gennaro E, Bruzzese F, Marchisio M, Carriero MV, Di Vizio D, Budillon A.

J Exp Clin Cancer Res. 2019 Jul 18;38(1):317. doi: 10.1186/s13046-019-1317-6.

2.

Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors.

Roca MS, Di Gennaro E, Budillon A.

J Clin Med. 2019 Jun 26;8(7). pii: E912. doi: 10.3390/jcm8070912. Review.

3.

Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake.

Piro G, Roca MS, Bruzzese F, Carbone C, Iannelli F, Leone A, Volpe MG, Budillon A, Di Gennaro E.

Mol Cancer Ther. 2019 Aug;18(8):1405-1417. doi: 10.1158/1535-7163.MCT-18-1117. Epub 2019 Jun 12.

PMID:
31189612
4.

A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges.

Lanuti P, Simeone P, Rotta G, Almici C, Avvisati G, Azzaro R, Bologna G, Budillon A, Di Cerbo M, Di Gennaro E, Di Martino ML, Diodato A, Doretto P, Ercolino E, Falda A, Gregorj C, Leone A, Losa F, Malara N, Marini M, Mastroroberto P, Mollace V, Morelli M, Muggianu E, Musolino G, Neva A, Pierdomenico L, Pinna S, Piovani G, Roca MS, Russo D, Scotti L, Tirindelli MC, Trunzo V, Venturella R, Vitagliano C, Zullo F, Marchisio M, Miscia S.

Sci Rep. 2018 Apr 11;8(1):5823. doi: 10.1038/s41598-018-24234-0.

5.

Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.

Terranova-Barberio M, Pecori B, Roca MS, Imbimbo S, Bruzzese F, Leone A, Muto P, Delrio P, Avallone A, Budillon A, Di Gennaro E.

J Exp Clin Cancer Res. 2017 Dec 6;36(1):177. doi: 10.1186/s13046-017-0647-5.

6.

Role of Oxygen Deposition Pressure in the Formation of Ti Defect States in TiO2(001) Anatase Thin Films.

Gobaut B, Orgiani P, Sambri A, di Gennaro E, Aruta C, Borgatti F, Lollobrigida V, Céolin D, Rueff JP, Ciancio R, Bigi C, Das PK, Fujii J, Krizmancic D, Torelli P, Vobornik I, Rossi G, Miletto Granozio F, Scotti di Uccio U, Panaccione G.

ACS Appl Mater Interfaces. 2017 Jul 12;9(27):23099-23106. doi: 10.1021/acsami.7b03181. Epub 2017 Jun 26.

7.

Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.

Caponigro F, Di Gennaro E, Ionna F, Longo F, Aversa C, Pavone E, Maglione MG, Di Marzo M, Muto P, Cavalcanti E, Petrillo A, Sandomenico F, Maiolino P, D'Aniello R, Botti G, De Cecio R, Losito NS, Scala S, Trotta A, Zotti AI, Bruzzese F, Daponte A, Calogero E, Montano M, Pontone M, De Feo G, Perri F, Budillon A.

BMC Cancer. 2016 Nov 25;16(1):918.

8.

Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.

Carbone C, Di Gennaro E, Piro G, Milone MR, Pucci B, Caraglia M, Budillon A.

Amino Acids. 2017 Mar;49(3):517-528. doi: 10.1007/s00726-016-2338-5. Epub 2016 Oct 19.

PMID:
27761756
9.

Synthesis of Arylpiperazine Derivatives as Protease Activated Receptor 1 Antagonists and Their Evaluation as Antiproliferative Agents.

Zotti AI, Di Gennaro E, Corvino A, Frecentese F, Magli E, Perissutti E, Cirino G, Roviezzo F, Terranova-Barberio M, Iannelli F, Caliendo G, Santagada V, Fiorino F, Budillon A, Severino B.

Anticancer Agents Med Chem. 2017;17(7):973-981. doi: 10.2174/1871520616666160926120904.

PMID:
27671294
10.

Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.

Ciardiello C, Roca MS, Noto A, Bruzzese F, Moccia T, Vitagliano C, Di Gennaro E, Ciliberto G, Roscilli G, Aurisicchio L, Marra E, Mancini R, Budillon A, Leone A.

Oncotarget. 2016 Apr 12;7(15):19559-74. doi: 10.18632/oncotarget.7195.

11.

A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).

Avallone A, Piccirillo MC, Aloj L, Nasti G, Delrio P, Izzo F, Di Gennaro E, Tatangelo F, Granata V, Cavalcanti E, Maiolino P, Bianco F, Aprea P, De Bellis M, Pecori B, Rosati G, Carlomagno C, Bertolini A, Gallo C, Romano C, Leone A, Caracò C, de Lutio di Castelguidone E, Daniele G, Catalano O, Botti G, Petrillo A, Romano GM, Iaffaioli VR, Lastoria S, Perrone F, Budillon A.

BMC Cancer. 2016 Feb 8;16:69. doi: 10.1186/s12885-016-2102-y.

12.

Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.

Terranova-Barberio M, Roca MS, Zotti AI, Leone A, Bruzzese F, Vitagliano C, Scogliamiglio G, Russo D, D'Angelo G, Franco R, Budillon A, Di Gennaro E.

Oncotarget. 2016 Feb 16;7(7):7715-31. doi: 10.18632/oncotarget.6802.

13.

Tunable spin polarization and superconductivity in engineered oxide interfaces.

Stornaiuolo D, Cantoni C, De Luca GM, Di Capua R, Di Gennaro E, Ghiringhelli G, Jouault B, Marrè D, Massarotti D, Miletto Granozio F, Pallecchi I, Piamonteze C, Rusponi S, Tafuri F, Salluzzo M.

Nat Mater. 2016 Mar;15(3):278-83. doi: 10.1038/nmat4491. Epub 2015 Dec 7.

PMID:
26641020
14.

Universal electronic structure of polar oxide hetero-interfaces.

Treske U, Heming N, Knupfer M, Büchner B, Di Gennaro E, Khare A, Di Uccio US, Granozio FM, Krause S, Koitzsch A.

Sci Rep. 2015 Sep 28;5:14506. doi: 10.1038/srep14506.

15.

Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.

Leone A, Roca MS, Ciardiello C, Terranova-Barberio M, Vitagliano C, Ciliberto G, Mancini R, Di Gennaro E, Bruzzese F, Budillon A.

Free Radic Biol Med. 2015 Dec;89:287-99. doi: 10.1016/j.freeradbiomed.2015.07.155. Epub 2015 Sep 26.

PMID:
26409771
16.

Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR2 and CD133, are not detectable in healthy peripheral and cord blood.

Lanuti P, Rotta G, Almici C, Avvisati G, Budillon A, Doretto P, Malara N, Marini M, Neva A, Simeone P, Di Gennaro E, Leone A, Falda A, Tozzoli R, Gregorj C, Di Cerbo M, Trunzo V, Mollace V, Marchisio M, Miscia S.

Cytometry A. 2016 Mar;89(3):259-70. doi: 10.1002/cyto.a.22730. Epub 2015 Aug 25.

17.

Photoresponse dynamics in amorphous-LaAlO3/SrTiO3 interfaces.

Di Gennaro E, Coscia U, Ambrosone G, Khare A, Granozio FM, di Uccio US.

Sci Rep. 2015 Feb 11;5:8393. doi: 10.1038/srep08393.

18.

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).

Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D'Angelo V, Granata C, Cavalcanti E, Maurea N, Maiolino P, Bianco F, Montano M, Silvestro L, Terranova Barberio M, Roca MS, Di Maio M, Marone P, Botti G, Petrillo A, Daniele G, Lastoria S, Iaffaioli VR, Romano G, Caracò C, Muto P, Gallo C, Perrone F, Budillon A.

BMC Cancer. 2014 Nov 24;14:875. doi: 10.1186/1471-2407-14-875.

19.

Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.

Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, Mattioli E, Iannuzzi CA, Budillon A, Giordano A, Pentimalli F.

Cell Cycle. 2014;13(4):652-65. doi: 10.4161/cc.27546. Epub 2013 Dec 17.

PMID:
24345738
20.

Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.

Bruzzese F, Pucci B, Milone MR, Ciardiello C, Franco R, Chianese MI, Rocco M, Di Gennaro E, Leone A, Luciano A, Arra C, Santini D, Caraglia M, Budillon A.

Cell Death Dis. 2013 Oct 24;4:e878. doi: 10.1038/cddis.2013.406.

21.

New perspective for an old antidiabetic drug: metformin as anticancer agent.

Leone A, Di Gennaro E, Bruzzese F, Avallone A, Budillon A.

Cancer Treat Res. 2014;159:355-76. doi: 10.1007/978-3-642-38007-5_21. Review.

PMID:
24114491
22.

Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.

Avallone A, Di Gennaro E, Silvestro L, Iaffaioli VR, Budillon A.

Expert Opin Drug Saf. 2014 Jan;13(1):113-29. doi: 10.1517/14740338.2014.845167. Epub 2013 Oct 5. Review.

PMID:
24093908
23.

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.

Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S, Capone F, Leone A, Di Gennaro E, Caraglia M, Budillon A.

Cell Death Dis. 2013 May 23;4:e641. doi: 10.1038/cddis.2013.165. Erratum in: Cell Death Dis. 2014;5:e1276.

24.

Control of the light transmission through a quasiperiodic waveguide.

T PR, Zito G, Di Gennaro E, Abbate G, Andreone A.

Opt Express. 2012 Nov 5;20(23):26056-61. doi: 10.1364/OE.20.026056.

PMID:
23187421
25.

Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/α-β catenins complex and multiple ErbB receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas.

Masuelli L, Budillon A, Marzocchella L, Mrozek MA, Vitolo D, Di Gennaro E, Losito S, Sale P, Longo F, Ionna F, Lista F, Muraro R, Modesti A, Bei R.

J Cell Physiol. 2012 Sep;227(9):3344-53. doi: 10.1002/jcp.24034.

PMID:
22213373
26.

Tissue transglutaminase: a new target to reverse cancer drug resistance.

Budillon A, Carbone C, Di Gennaro E.

Amino Acids. 2013 Jan;44(1):63-72. doi: 10.1007/s00726-011-1167-9. Epub 2011 Dec 1. Review.

27.

Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells.

Bianchi L, Bruzzese F, Leone A, Gagliardi A, Puglia M, Di Gennaro E, Rocco M, Gimigliano A, Pucci B, Armini A, Bini L, Budillon A.

Proteomics. 2011 Sep;11(18):3725-42. doi: 10.1002/pmic.201100092.

PMID:
21761561
28.

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.

Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Di Gennaro E, Budillon A.

J Cell Physiol. 2011 Sep;226(9):2378-90. doi: 10.1002/jcp.22574.

PMID:
21660961
29.

Synthesis of 1-naphtylpiperazine derivatives as serotoninergic ligands and their evaluation as antiproliferative agents.

Fiorino F, Magli E, Perissutti E, Severino B, Frecentese F, Esposito A, De Angelis F, Incisivo GM, Massarelli P, Nencini C, Di Gennaro E, Budillon A, Di Cintio A, Santagada V, Caliendo G.

Eur J Med Chem. 2011 Jun;46(6):2206-16. doi: 10.1016/j.ejmech.2011.03.001. Epub 2011 Mar 8.

PMID:
21440338
30.

Experimental evidence of cut-wire-induced enhanced transmission of transverse-electric fields through sub-wavelength slits in a thin metallic screen.

Di Gennaro E, Gallina I, Andreone A, Castaldi G, Galdi V.

Opt Express. 2010 Dec 20;18(26):26769-74. doi: 10.1364/OE.18.026769.

PMID:
21196953
31.

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.

Di Gennaro E, Piro G, Chianese MI, Franco R, Di Cintio A, Moccia T, Luciano A, de Ruggiero I, Bruzzese F, Avallone A, Arra C, Budillon A.

Br J Cancer. 2010 Nov 23;103(11):1680-91. doi: 10.1038/sj.bjc.6605969. Epub 2010 Nov 2.

32.

Superlensing properties of one-dimensional dielectric photonic crystals.

Savo S, Di Gennaro E, Andreone A.

Opt Express. 2009 Oct 26;17(22):19848-56. doi: 10.1364/OE.17.019848.

PMID:
19997206
33.

Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.

Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A.

Mol Cancer Ther. 2009 Nov;8(11):3075-87. doi: 10.1158/1535-7163.MCT-09-0254. Epub 2009 Nov 3.

34.

Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis.

Di Cintio A, Di Gennaro E, Budillon A.

Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):1-13.

PMID:
19663772
35.

Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed.

Di Gennaro E, Bruzzese F, Pepe S, Leone A, Delrio P, Subbarayan PR, Avallone A, Budillon A.

Cancer Biol Ther. 2009 May;8(9):782-91. Epub 2009 May 9.

PMID:
19270508
36.

Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer.

Luciani A, Bertuzzi C, Ascione G, Di Gennaro E, Bozzoni S, Zonato S, Ferrari D, Foa P.

Lung Cancer. 2009 Oct;66(1):94-6. doi: 10.1016/j.lungcan.2008.12.019. Epub 2009 Jan 26.

PMID:
19171407
37.

Pendellösung effect in photonic crystals.

Savo S, Di Gennaro E, Miletto C, Andreone A, Dardano P, Moretti L, Mocella V.

Opt Express. 2008 Jun 9;16(12):9097-105.

PMID:
18545621
38.

Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.

Budillon A, Di Gennaro E, Bruzzese F, Rocco M, Manzo G, Caraglia M.

Recent Pat Anticancer Drug Discov. 2007 Jun;2(2):119-34. Review.

PMID:
18221057
39.

The ribosomal P0 protein induces a spontaneous immune response in patients with head and neck advanced stage carcinoma that is not dependent on its overexpression in carcinomas.

Bei R, Masuelli L, Trono P, Orvietani PL, Losito S, Marzocchella L, Vitolo D, Albonici L, Mrozek MA, Di Gennaro E, Lista F, Faggioni G, Ionna F, Binaglia L, Manzari V, Budillon A, Modesti A.

Int J Oncol. 2007 Dec;31(6):1301-8.

PMID:
17982655
40.

Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.

Avallone A, Di Gennaro E, Bruzzese F, Laus G, Delrio P, Caraglia M, Pepe S, Comella P, Budillon A.

Anticancer Drugs. 2007 Aug;18(7):781-91.

PMID:
17581300
41.

Experimental evidence of s-wave superconductivity in bulk CaC6.

Lamura G, Aurino M, Cifariello G, Di Gennaro E, Andreone A, Emery N, Hérold C, Marêché JF, Lagrange P.

Phys Rev Lett. 2006 Mar 17;96(10):107008. Epub 2006 Mar 16.

PMID:
16605783
42.

Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.

Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A.

Clin Cancer Res. 2006 Jan 15;12(2):617-25.

43.

[Aspergillus fumigatus in nasopharyngeal cavity of horses].

Guida N, Mesplet M, Di Gennaro E, Digilio P, Moras EV.

Rev Iberoam Micol. 2005 Sep;22(3):160-2. Spanish.

44.

Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells.

Caraglia M, Giuberti G, Marra M, Di Gennaro E, Facchini G, Caponigro F, Iaffaioli R, Budillon A, Abbruzzese A.

Front Biosci. 2005 Sep 1;10:2566-75.

PMID:
15970518
45.

Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase.

Budillon A, Bruzzese F, Di Gennaro E, Caraglia M.

Curr Drug Targets. 2005 May;6(3):337-51. Review.

PMID:
15857292
46.

Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients.

Bei R, Budillon A, Masuelli L, Cereda V, Vitolo D, Di Gennaro E, Ripavecchia V, Palumbo C, Ionna F, Losito S, Modesti A, Kraus MH, Muraro R.

J Pathol. 2004 Nov;204(3):317-25.

PMID:
15476268
47.

Acetylation of proteins as novel target for antitumor therapy: review article.

Di Gennaro E, Bruzzese F, Caraglia M, Abruzzese A, Budillon A.

Amino Acids. 2004 Jul;26(4):435-41. Epub 2004 Jun 11. Review.

PMID:
15290351
48.

Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.

Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S, Budillon A.

J Cell Physiol. 2003 Apr;195(1):139-50.

PMID:
12599217
49.

Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).

Caponigro F, Comella P, Rivellini F, Avallone A, Budillon A, Di Gennaro E, Mozzillo N, Ionna F, De Rosa V, Manzione L, Comella G.

Ann Oncol. 2000 May;11(5):575-80.

50.

8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor.

Budillon A, Di Gennaro E, Caraglia M, Barbarulo D, Abbruzzese A, Tagliaferri P.

Br J Cancer. 1999 Dec;81(7):1134-41.

Supplemental Content

Loading ...
Support Center